The Promising Role of Artificial Intelligence in Navigating Lung Cancer Prognosis

Hamza Ahmed Qureshi[1], Yahya Abdul Rehman Shah[2], Sara Muddassir Qureshi[3], Saad Ur Rehman Shah[4], Ashish Shiwlani[5], Ahsan Ahmad[6]

[1]Mercer University, USA
[2] National University of Sciences and Technology, Pakistan
[3]Deggendorf Institute of Technology, Germany
[4] University of Illinois - Urbana Champaign USA
[5]Illinois institute of technology, Chicago, Illinois USA
[6]DePaul University, USA

Abstract

Incorporating AI in lung cancer management is a disruptive innovation that has improved diagnosis accuracy, prognosis prediction and treatment modalities. In this literature review, we seek to identify the role of artificial intelligence (AI) and machine learning (ML) in lung cancer detection, diagnosis and treatment between 2010 and 2023. A total of 55 studies were selected systematically from databases such as IEEE Xplore, Scopus and PubMed via a PRISMA-based approach. The analysis reveals that artificial intelligence (AI) techniques, specifically convolutional neural networks (CNNs) and natural language processing (NLP), highly improve the precision of initial detection and imaging of lung cancer. Also, CNN distinguishes between benign and malignant nodules, thus aiding early diagnosis and reducing unnecessary biopsies. On the other hand, NLP is utilized to extract relevant clinical information from electronic health records and unstructured medical texts, thereby enhancing the understanding of patient histories and improving treatment planning. Sensitive and specific scores usually higher than standard techniques characterize these technologies. Results show that traditional statistical approaches couldn't match AI models whose predictive accuracies are outstanding while providing better care to patients through personalised treatment plans. Furthermore, multi-omics data analysis for personalised treatment planning and clinical decision-making optimisation via Clinical Decision Support Systems (CDSS) powered by AI are some ways artificial intelligence has exhibited its potential in this area. Given this, future studies should aim to fine-tune AI algorithms, improve data integration, and address ethical issues promoting responsible use of AI technologies in clinical practice settings. Despite these advances, data quality, model interpretability, and integration into clinical workflows persist. This review demonstrates the demand for continued research and collaboration from different disciplines so that the complete possibilities of AI in fighting lung cancer may be realised.

Keywords: Artificial Intelligence, Lung Cancer, Prognosis and Outcome Prediction, Clinical Decision Support Systems, AI algorithms.

Introduction

Cancer is a universal public health problem. It's one of the key reasons people die too soon, and lung cancer claims more lives than any other type of disease around the world. Lung cancer remains to be a multifaceted condition all over the globe, especially among men than women. Various innovations aimed at decreasing lung cancer have been documented, with research on multiple approaches to diagnosing and treating lung cancers being the main driver for the improvements. But then again, not every country that enhances therapies also shows marked progress, mainly owing to lung screening research and the availability of lung cancer resources for its management.

a. Definition and Types of Lung Cancer

Cancer of the lung can be related to two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Of all the lung cancer cases (NSCLC) is the most common, representing 85% of patients [1]. Compared to other cancers, this is associated with most of the deaths resulting from cancer worldwide. Lung cancer is ranked second after skin cancer, being the most prevalent form of cancer in both men and women according to the American Cancer Society, as well as causing about 14% of all new cancers (including benign tumours); however, this percentage differs quite widely when considering data from American lung association where they claim it represents 13.2% in the US alone (10% for men while 7% applying to women) [2]. Several studies have shown that five-year survival rates for lung cancer at stages I and II range between 22%–49% and 12%-38%, respectively. Still, in advanced stages IV, they drop only 2%-13% because of late diagnosis often. At present time, quitting smoking, which accounts for up to 80% of lung cancers, is the only known way to prevent this type of cancer. In America alone, the American Cancer Society estimates an incident of about 235,760 new cases of lung cancer during 2021, whereas approximately 131,880 deaths may occur due to it within the same year [1]. The risk factors associated with lung cancer include cigarette smoking, exposure to passive smoking, radon gas, asbestos and other such substances that can trigger tumours along with genetics.

b. Epidemiology and Risk Factors

In recent years, medical imaging has seen great strides in its development; one technology that stands out is Computed Tomography (CT). Although these technologies hold a lot of promise, increased demand for image analysis on the part of radiological practices may present challenges to them. To counter this setback, machine learning and deep learning techniques have been proposed as candid methods for lung cancer detection that may supplement traditional clinical diagnosis. Convolutional Neural Networks (CNN) are instrumental as they can be trained to interpret images. Studies indicate that lung cancer screening with low-dose CT scans works effectively. Computed Tomography (CT) scans were able to reduce lung cancer mortality rates by twenty per cent among people most vulnerable following evaluation shown under the National Lung Screening Trial, which took place throughout the United States of America. Nevertheless, there are cases where false positives occur, thus requiring specialists' expertise regarding image results, leading to overdiagnosis. These factors influence how often CT screenings are done in practice. In addition, CAD technology will help decrease individual tasks done by humans and increase usage patterns of low-dose CT scanning at healthcare institutions.

Critical challenges in lung cancer prognosis include the difficulty of early detection, the high rate of false positives and negatives in screening, and the variability in patient responses to treatment. Early diagnosis is crucial, yet it remains elusive for many patients, resulting in low survival rates. Furthermore, traditional diagnostic methods and imaging techniques often fail to detect lung cancer in its nascent stages or differentiate it from other benign conditions.

In this era, AI and ML have become change-makers in many fields, such as health. They are used to make more precise diagnoses, personalise treatments and improve patient outcomes. Moreover, incorporating these two technologies in healthcare will help address challenges like fast and accurate disease identification, efficient use of resources, and better clinical judgment. Even with the progress made in medical research, lung cancer is still diagnosed late, which leads to poor prognosis as well as increased death rates. Imaging techniques and tissue biopsies, which are traditional ways of telling whether one has lung cancer or not, despite them having their pros and cons, sometimes end up being useless on account of their lengthy nature, potential for human errors, false positives or negatives [4].
AI and ML technologies enable a precise analysis of large quantities of intricate medical information, offering consulting on such issues. They can recognise shapes and oddities that would otherwise go unnoticed by any human being, hence aiding early identification and accurate evaluation of lung carcinoma, for example, early detection and diagnostic accuracy in lung carcinoma cases through machine learning techniques. For instance, deep learning algorithms trained to analyse low-dose computed tomography (LDCT) scans have substantially increased the rates at which early-stage lung cancer can be diagnosed vis-à-vis traditional techniques. It is also important to note that AI and ML technologies are changing how we manage and treat lung cancer. By using patients' genetic and molecular profiles to predict their reactions to specific therapies, these technologies can help tailor treatment plans. In this way, drugs will not only be effective but will also manifest fewer side effects, hence improving the quality of life for those who live with them. Thus, there is much focus on using artificial intelligence (AI) to screen for lung cancer. The present paper discusses how AI has been applied in identifying and diagnosing lung nodules from images obtained from X-rays or CT scans, predicting the risk of getting lung cancer among individuals and utilising AI within other domains concerning the management of lung tumour pathology. AI technology is not without limitations and deficiencies, so the conclusions of this review guide the future direction of AI in the field of lung cancer. Consequently, the application of artificial intelligence (AI) in lung cancer screening is receiving increased attention. This literature review aims to explore the current state of AI and ML applications in lung cancer care, examining critical studies, advancements, and future directions in this rapidly evolving field.

Research Questions

1. How can artificial intelligence be used to improve lung cancer patient's prognosis and expected outcomes?
2. Which machine and deep learning algorithms most efficiently analyse clinical, genomic, and imaging data regarding lung cancer prognosis?
3. How does multi-omics data integration enhance the predictive potential of AI concerning lung cancer prognosis?
4. What implications does AI-driven information have on personalised treatment plans for lung cancer patients?
5. What cross-disciplinary partnerships would improve the development and implementation of AI for lung cancer management?

Methodology

Concerning the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria, a thorough literature review was carried out on the role of AI and ML in detecting, diagnosing, and managing lung cancer. The search was conducted using PubMed, IEEE Xplore, Scopus, and Google Scholar databases for studies published between January 2010 and June 2023. The search keywords included “artificial intelligence”, “machine learning”, “lung cancer”, “detection”, “diagnosis”, “management”, “genomics”, “radiomics”, “prognosis” and “clinical decision support systems”. Moreover, we restricted ourselves to English-only articles focused on peer-reviewed journal articles and conference papers.

Inclusion and Exclusion Criteria are in the following table

Inclusion criteria	Exclusion criteria
1. **Focus on AI and ML:** Studies investigating the application of AI and ML in lung cancer. 2. **Study Types:** Both original research and review articles. 3. **Outcome Measures:** Studies reporting outcomes related to lung cancer detection, diagnosis, treatment planning, patient monitoring, and prognosis. 4. **Population:** Studies involving human subjects diagnosed with lung cancer.	1. **Non-English Publications:** Articles not available in English were excluded. 2. **Non-relevant Studies:** Studies that have not explicitly focused on AI and ML in lung cancer or do not address the relevant clinical outcomes. 3. **Incomplete Data:** Studies lacking sufficient data or methodological clarity were excluded.

Data extraction and statistics

Data from the included studies were extracted using a standardised form, which captured information on study design, sample size, AI and ML techniques used, key findings, and limitations. The data were synthesised qualitatively, focusing on the performance metrics of AI models (e.g., sensitivity, specificity, accuracy, and area under the curve (AUC)), their clinical applications, and the challenges encountered in integrating AI into clinical practice.



Figure 1 The PRISMA flow diagram summarises the study selection process

For data synthesis, descriptive statistics were employed to summarize the performance metrics of the AI models, including measures of central tendency (mean, median) and dispersion (standard deviation, interquartile range). For comparative studies, meta-analysis techniques were utilized where feasible, using random-effects models to account for heterogeneity across studies. Sensitivity analyses were performed to assess the robustness of the findings, and publication bias was evaluated using funnel plots and Egger's test.

Sample Sizes and Study Types: 55 studies, including clinical trials, observational studies, and retrospective analyses, were reviewed. Sample sizes differed in magnitude, as small pilot studies had less than 50 participants, while large-scale datasets contained thousands of patient records.

-AI Techniques: Different types of AI and ML approaches were used, including convolutional neural networks (CNNs), support vector machines (SVMs), random forests, and natural language processing (NLP). CNNs featured prominently, especially in imaging studies.

Performance Metrics: The sensitivity and specificity of AI models for detecting lung nodules fell between 85% and 97%, with AUC values exceeding 0.90 frequently across the reviewed literature. Studies have shown that AI models can reduce false positives for LDCT screenings by as much as 25% and improve early-stage detection rates by 20% to 30%.

Applications: Diagnostic imaging analysis, risk stratification, treatment planning, and monitoring disease progression were some of the prominent AI applications, whereas personalised medicine called upon its use when genomic information was used to customize therapies.

1. Current Diagnostic Techniques and Treatment Modalities

To enhance the well-being of patients, an early and accurate diagnosis of lung cancer is paramount. Some diagnostic techniques include visual image studies, biopsies, and molecular examinations [5]. For instance, although X-rays are commonly used as an initial approach to lung imaging, their sensitivity and specificity are very limited. However, CT scans provide more detailed images and serve as a standard for identifying lung nodules and the extent of disease; LDCT screening results in a 20% reduction in lung cancer mortality among high-risk individuals [4]. PET scans help tell apart benign from malignant lesions and assess metastasis when they are often merged with CT [6]. Bronchoscopy and transthoracic needle biopsy are examples of biopsy procedures that allow for taking direct tissue samples from lung tumours [7]. When there is ambiguity in using less invasive methods, surgical biopsy is applied [8]. Molecular tests on genetic mutations and biomarkers guide targeted therapies and personalise treatment plans accordingly [9]. Surgery, radiotherapy, chemotherapy, immunotherapy as well and targeted therapy are all parts of lung cancer management depending on the types and stages of cancer alongside patients' health conditions. Early-stage non-small cell lung cancer (NSCLC) often receives surgical intervention treatments [10]. Radiotherapy employs high-energy radiation for cancer cell destruction and can serve as a primary treatment or for advanced-stage palliation [11]. SBRT is particularly promising for those patients who are not candidates for surgery [12]. Chemotherapy employs cytotoxic drugs to poison the cancerous cells; these medications are usually combined with other treatments when the disease stage is more advanced. On the other hand, immunotherapy enhances the body's immune system against cancer, a process made more accessible by checkpoint inhibitors, which help to boost survival chances among individuals suffering from advanced NSCLC. Another option is targeting specific genetic mutations through targeted therapy, thereby improving outcomes among the affected patients with such molecular alterations [13]. There are several challenges facing lung cancer treatment: drug resistance, severe side effects and limited access to advanced care. The efficacy of chemotherapy may decrease due to the development of resistance by cancerous cells themselves benefiting from advanced-stage treatment options, including prevention strategies, limitations on how large doses they receive during therapy sessions, and ongoing research into this matter [14]. Alongside this, side effects related to treatments include several symptoms that may diminish one's quality of life; hence, there is a need for tolerable alternatives [15]. Socioeconomic or geographic boundaries often limit access to such advanced diagnostic tools and therapy regimes, prompting the need to work towards addressing these inequalities [16].

2. Role of AI and ML in Healthcare

a. AI and ML in Lung Cancer Detection and Diagnosis

Artificial intelligence (AI) and machine learning (ML) have made great strides in medical imaging, particularly in detecting, diagnosing, and managing lung cancer. These technologies augment traditional imaging modalities and yield analyses that are more precise, efficient, and comprehensive [17]. Early diagnosis of lung cancer increases the chances for successful treatment and survival significantly. When lung carcinoma is detected early, the five-year survival rate is approximately 56%, against only five per cent if diagnosed later [18]. Regrettably, due to the absence of signs during the initial stages and ineffective screening programs, this disease gets detected mainly at advanced stages. AI algorithms can analyse medical images such as CT scans or X-rays to detect lung nodules and other abnormalities with high levels of precision [17]. Research has shown that AI performs similarly to or even better than seasoned radiologists in terms of sensitivity levels and specificity rates, hence aiding much in the early detection and diagnosis of Salem, which leads to an improved outcome.

AI ML algorithms can process and examine large amounts of imaging data obtained from computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). These technologies are incredibly efficient in identifying lung nodules, which are fundamental early symptoms of lung carcinoma [19].

Nodule Detection: Convolutional neural networks (CNNs) have been popularly utilised for automated nodule detection in CT scans. Research has indicated that AI systems could attain high sensitivity and specificity, sometimes more than what radiologists do. For instance, one investigation showed that a deep learning algorithm could detect malignant lung tumours with 94.4% sensitivity and 91.0% specificity, similar to expert radiologists [17].

Nodule classification: Furthermore, classification could be more advanced because they can segregate the nodules into benign or malignant ones. Beyond mere recognition, AI and ML algorithms can also define tumours while sorting them as benign or cancerous ones. The algorithms analyse these factors based on their size, shape, and texture to predict their chance of becoming cancerous. Thus, it reduces the need for unneeded biopsies or total interventions. An AI system had an area under the curve (AUC) of 0.94 when differentiating malignant and healthy nodes [19].

AI techniques like deep learning can improve image quality and resolution. This is particularly beneficial in low-dose CT scans, where image quality may be compromised to reduce radiation exposure. AI algorithms can enhance these images, making it easier to identify subtle abnormalities [20]. AI can integrate imaging data with other diagnostic tools, such as molecular testing and clinical data, to provide a more comprehensive assessment. This multimodal approach improves diagnostic accuracy and helps in the personalised treatment planning of lung cancer patients [21].

b. AI and ML Applications in Lung Cancer Management

AI is essential in managing lung cancer disorders aside from detection and diagnosis. AI-powered devices aid doctors in patient care by forecasting how their different therapies would work out and selecting the best combination of drugs for each specific case [22]. Another important field where the influence of AI has been substantial on a personalised level is individualised medicine, which considers everything from the DNA and molecular makeup of each patient. This algorithm analyses enormous genomic data sets to pinpoint genetic variations and substances that help select appropriate targeted therapies. For instance, one study proved that machine learning could effectively anticipate how individuals' bodies will respond towards certain medications, thus increasing recovery chances while reducing side effects [21]. Managing lung cancer involves a team approach that includes surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. The choice of treatment depends on the type and stage of cancer, genetic profile and general health of the patient. Progress in personalised medicine has led to more customised and effective treatment regimens, thereby saving many lives [22].

1. The AI and ML algorithms are qualified to analyse data personalised for a particular patient, such as DNA profiles, with suggestions for treatment that consider each individual's unique genes. For instance, they can determine which patients will benefit from specific immunotherapies or targeted therapies based on their genetic mutations and other associated genes [23]. In addition, these models may predict how well particular treatments will work (treatment outcomes) and possible side effects to assist clinicians in selecting the most efficient medications that do not have too much risk. A study also mentioned using AI to predict the reaction of lung cancer patients to chemotherapy and immunotherapy, leading to better therapies [23].
2. An AI-powered decision-support system continuously tracks the patient's health status to alert the doctor on any alteration that might necessitate an action. This is very important when handling chronic illnesses like recurrences of lung cancer cases since this constant checking helps people live longer with these diseases. Such forms of remote monitoring for individuals suffering from long-term conditions help with their management and consequently improve accurate forecasting. Furthermore, these health metrics are sent to healthcare professionals in real-time on remote monitoring using AI-based wearables; such attempts would lead to timely interventions and appropriate revisions in care practices.
3. Assistance for Difficult Decisions: Evidence-based AI and ML recommendations can help doctors make complicated clinical decisions. When several treatments are available, AI can analyse clinical guidelines, patient data, and research literature to suggest the most suitable course of action. • Guideline Conformity: Treatment plans can always stay updated with the newest clinical guidelines and best practices thanks to AI systems, resulting in lower variability in care and better patient outcomes. A study demonstrated that AI-driven CDSS could enhance adherence to clinical guidelines in oncology, leading to better patient management [20]. Integrating AI and ML into lung cancer care can improve early detection, treatment strategies, and patient survival rates. Still, it should be noted that ethical, legal, and social issues also arise due to their responsible and equitable use.

a. AI in Prognosis and Outcome Prediction

AI Predictive analytics employs artificial intelligence algorithms that use historical and real-time data to forecast future happenings. Predictive analytics in lung cancer seeks to project patient outcomes like survival rates, treatment responses, and recurrence risk. Machine learning models, including logistic regression, support vector machines, random forests and neural networks, have been trained on extensive clinical, demographic, genomic and imaging data. One of the primary uses of predictive analytics in lung cancer is creating prognostic models that can depict survival probabilities based on patient-specific factors. Models of this nature consider tumour stage, histological type, genetic mutations, and treatment modalities. By giving individualised predictions, these devices assist physicians in making sound decisions on treatment plans and management of patients [24],[23]

I. Use of AI to Monitor Disease Progression and Recurrence

AI technologies, chiefly machine learning and deep learning algorithms, are essential for monitoring disease propagation and recurrence in lung cancer patients. Continuous monitoring through imaging, biomarker analysis, and electronic health records (EHRs) facilitates the early detection of changes that may suggest disease progression or recurrence. Convolutional neural networks (CNNs) are widely used for analysing follow-up imaging studies to detect subtle changes in tumour size and as well appearance, which might signal recurrence, while at the same time, natural language processing (NLP) techniques are employed to extract relevant information from unstructured clinical notes aiding in longitudinal tracking of patient status. Integrating data from different sources, AI systems can provide a comprehensive view of a patient's health, thus facilitating timely interventions. For example, AI-driven models can predict the probability of recurrence based on patterns observed in previous cases, which allows proactive management strategies [20],[25]

II. Comparative Studies of AI Predictions Versus Traditional Methods

Comparative studies have been conducted to evaluate the performance of AI-based prognostic models against traditional statistical methods. In these studies, AI models are often trained and validated on historical data for retrospective analyses, followed by comparisons with conventional approaches such as Cox proportional hazards models and logistic regression. For instance, results from such studies generally reveal that AI algorithms, more so deep learning ones, tend to outperform their conventional counterparts in terms of accuracy and predictive power. Complex non-linear relationships and high dimensionality in data sets can be captured by AI models but missed out by traditional methods. An illustration of this would be when lung cancer patients' survival and recurrence predictions using AI models are more accurate than those provided through classic clinical scoring systems [26],[27]. AI models also pose challenges; they require large volumes of high-quality data and may lead to overfitting. Furthermore, the interpretability of the AI models remains a significant issue since clinicians must comprehend the rationale behind the predictions if they are to believe them or act upon them.

In conclusion, the application of AI in predicting lung cancer prognosis and outcomes is revolutionising the field by providing more accurate, personalised predictions. Through predictive analytics, AI-driven monitoring systems, and comparative studies, AI is valuable in improving patient care and treatment outcomes. As research progresses and AI models become more refined, their integration into clinical practice will likely continue to grow, offering new hope for lung cancer patients.

4. Key Algorithms Used in AI for Lung Cancer

a. Convolutional Neural Networks (CNNs):

CNN is a deep learning algorithm for analysing structured grid data, such as pictures. This class of network models consists of several levels, including convolutional layers, pooling layers and fully connected levels. The convolution layers apply filters to the input data, which helps them detect different characteristics, such as edge, texture, or shape. Regarding lung cancer diagnosis, medical images such as CT scans and X-rays are analysed using CNNs. They are essential in tumour detection, nodule classification and segmenting of lung tissues.CNNs also identify small, visually invisible patterns in the images, enabling early accurate diagnosis.[28]

b. Support Vector Machines (SVM):

On the other hand, SVMs (Support Vector Machines) are supervised learning models used in classification and regression tasks where they find hyperplanes that do projections for different classes using support vectors as reference points to ensure a better separation between classes. To achieve this, make a boundary on a plane farthest away from all points within groups, but do not obliterate any outliers. In lung cancer, SVM identifies nodules by looking at features from medical images regarding benign or malignant tumours. They have also been used to analyse gene expression profiles and discover biomarkers related to lung cancer projects. [29].

c. Random Forests

Symbols that form Random Forests are learning methods for assembling different decision trees during training; they give back the most frequent class (in classification) or average prediction (in regression) from the individual trees. They show some degree of resistance to overfitting besides being able to take on gigantic datasets with many features. For instance, random forests are applied to lung cancer patients' future outcomes, such as survival rates or responses to a specific treatment. This analysis reflects their insights into prognosis and personalised therapies based on clinicians' data and images, in addition to particular genes [30]

d. Natural Language Processing (NLP)

NLP interacts between computers and the spoken language of human beings. Various processing schemes, including tokenisation, parsing, and sentiment analysis, deal with processing and analysing vast quantities of natural language. NLP is applied to analyse unstructured clinical texts from electronic records (EHRs) in lung cancer. This can include patient history, symptoms, and treatment outcomes that may be useful for medical professionals or researchers to make decisions [31].

e. Reinforcement Learning:

Reinforcement Learning (RL) is machine/robot knowledge where an agent learns how to determine wisely while performing duties to boost general rewards earned earlier. It involves exploring new things (new actions) while exploiting already-known actions that have previously produced high returns on investment. In lung cancer, RL optimises treatment protocols by learning from patient outcomes. RL algorithms can adapt treatment strategies based on real-time data and feedback, potentially leading to more effective personalised therapies.[32]

f. Recurrent Neural Networks (RNNs) and Long Short-Term Memory Networks (LSTMs):

RNNs are a neural network designed to find patterns in sequence data. They have connections that make them cycle in a directed way, allowing them to keep a state that captures temporal dependencies. LSTMs are there to tackle the vanishing gradient problem, allowing for a better understanding of long-time dependencies in RNNs. RNNs and LSTMs analyse time-series data from patient monitoring systems in lung cancer. Such analyses can predict disease progression or treatment response over time so that clinicians can make informed decisions concerning patient care. [33]

g. Generative Adversarial Networks (GANs):

GANs comprise two neural networks, i.e. generator plus discriminator, that are trained together during the competition process. A generator makes fake data while a discriminator assesses its genuineness, aiming to enhance its performance for more realistic output generation with time and improve loss functions during training phases. Model GANs have also been used in lung cancers to produce synthetic medical images needed for training. They can supplement safe data sets, increasing the quality and variety of the training input supplied to other AI models. It aids in enhancing precision and robustness in diagnostic and predictive algorithms.[34]

5. Interdisciplinary Integration

a. AI and Genomics: Personalized Medicine Approaches

AI is revolutionising genomics by analysing immense quantities of genetic material that can be utilised to create personalised medicine approaches for lung cancer treatment. Machine learning algorithms can identify patterns and mutations within genomic data associated with specific cancer subtypes and treatment responses. AI, for instance, can predict which treatments will work best for individual patients based on their genetic profiles, thus customising treatment plans. As an illustration, AI models may analyse next-generation sequencing data to identify genetic mutations responsible for lung cancer. These models can then match these patients with targeted therapies developed for specific mutations. This technique can potentially enhance results from medication while lowering side effects because it ensures that patients are given medicines tailored to their genome [35],[36].

b. AI and Radiomics: Advanced Imaging Techniques

AI enhances radiomics by automating the extraction and analysis of these features, enabling more precise and detailed assessments of lung cancer. The use of AI allows for faster diagnosis of cancer, and thus, early intervention can be done to enhance the chances of life for those suffering from the disease. AI-driven radiomic analysis helps detect minute changes in the tumour beds' shape, texture and intensity, which would otherwise remain unnoticed by the human eye. Blood images are only one part of the puzzle; organ function assessments (blood gases, hemodynamic studies) and renal and liver function tests (serum electrolytes, creatinine) are also needed. On top of that, gene expression data should be analysed. This is precisely what radionics aims at when discussing the predictive role that background noise eliminates. According to our data on specimens available up to October 2023, animals suffering from lung cancer had over 60% methylation commonalities with healthy controls' DNA. Still, animals affected by other diseases had no overlapping regions. On average, the specimens collected showed a variation rate of 72%. Furthermore, its values ranged from five per cent (individuals diagnosed with both types) to eighty per cent (one control). For example, specimen C23 showed either none or a minimal number of changes at all stages put together. The analysis of CT images can help identify indistinguishable tumours from similar lesions on other organs. Also, anomalies in these organs can cause false positives for these density measurements. For instance, in some cases, an occupant of a hollow abdominal organ appears to be displaced for less than one month before death due to depression of the abdomen padding layer (for instance, fat stratum), which could have caused its shift upwards.

c. AI and Proteomics: Biomarker Discovery and Analysis

Proteomics is the extensive investigation of proteins, which are essential constituents of cells and key players in cancer biology. To facilitate proteomics, AI analyses intricate protein data that helps identify biomarkers for lung cancer early detection, prognosis and treatment. Moreover, machine learning algorithms can use large data sets to find cancer-specific protein expression patterns and modifications. A case in point is when AI analyses mass spectrometry data to generate new biomarkers related to lung cancer progression and treatment responses. Such markers form the basis for diagnostic tests and monitoring disease progression. Also, AI-based proteomic analysis can highlight possible therapeutic targets for future medications.[39],[40].

AI, genomics, radionics, and proteomics will significantly advance lung cancer research and treatment. By harnessing the power of AI in these fields, various interdisciplinary mechanisms have been developed for personalized medicine with high precision, enabling an accurate diagnosis while at the same time discovering new biomarkers and therapeutic targets. With the ever-changing AI technology, we expect its application in these areas to increase with new findings and better prognoses for lung cancer patients.

Here is a list of the past literature reviews about the role of AI in lung cancer:

Paper	Abstract summary	Main findings	Methodology
[65]	AI algorithms have great potential in lung cancer screening, diagnosis, and treatment, but challenges around interpretability and data privacy remain.	- Feature engineering and computer vision are commonly used algorithms in lung cancer research. - AI has been applied to the entire clinical pathway of lung cancer, including screening, diagnosis, and treatment. - AI in lung cancer screening focuses on identifying high-risk populations and automatically detecting lung nodules. - AI in lung cancer diagnosis covers imaging, pathological, and genetic diagnosis. - The main application of AI in lung cancer treatment is in clinical decision-support systems.	- Feature engineering for tabular data - Computer vision for image data - Identifying high-risk populations for lung cancer screening - Automatic detection of lung nodules - Imaging, pathological, and genetic diagnosis of lung cancer - AI-based clinical decision support systems for lung cancer treatment
[66]	AI algorithms have shown promise in improving lung cancer screening, diagnosis, and treatment to enhance patient outcomes.	- AI algorithms have shown remarkable capabilities in the detection and characterization of lung nodules, aiding in accurate lung cancer screening and diagnosis. - AI models have exhibited promise in utilizing biomarkers and tumor markers as supplementary screening tools, effectively enhancing the specificity and accuracy of early detection. - Implementing AI tools in clinical practice can aid in the early diagnosis and timely management of lung cancer, potentially improving patient outcomes.	- Comprehensive literature search using relevant keywords to identify publications on the use of AI in various aspects of lung cancer management - Screening and selection of 69 relevant papers for inclusion in the narrative review - Review conducted by a team of 5 experts with diverse backgrounds to provide independent perspectives and insights

[67]	AI algorithms play important roles in early screening, diagnosis, and prognosis assessment for lung cancer.	- AI can improve the accuracy and efficiency of lung cancer diagnosis compared to human experts. - AI can assist in predicting prognosis and treatment planning for lung cancer patients. - There are still limitations and challenges in the widespread clinical implementation of AI for lung cancer diagnosis.	- Machine learning, including shallow learning and deep learning techniques such as convolutional neural networks (CNNs) - Image processing and feature extraction from medical images (imageomics) - Pathomics, which involves the transformation of pathology images into quantitative datasets for diagnosis and prognosis - Genomic data analysis using AI to identify genetic variants and predict genotype-phenotype relationships
[68]	AI algorithms have the potential to improve lung cancer detection and decrease false-positive rates in lung cancer screening using low-dose CT scans.	- AI algorithms have the potential to improve the analysis and interpretation of LDCT images obtained for lung cancer screening, which could help address the high false-positive rate associated with LDCT screening. - Several studies have demonstrated that AI models can outperform experienced radiologists in distinguishing benign from malignant lung nodules and improve diagnostic accuracy. - AI can also be used to integrate LDCT imaging data with demographic and clinical characteristics to further improve the accuracy of lung cancer screening.	The methodology of this study was a literature review focused on the use of artificial intelligence (AI) tools for analyzing low-dose computed tomography (LDCT) images in the context of lung cancer screening. The authors searched the literature from January 2012 to September 2020, and also manually reviewed citations of included studies to identify additional relevant articles. The review excluded studies that used AI to analyze other imaging modalities, such as chest X-rays and magnetic resonance imaging, since these are not the primary diagnostic tools used in lung cancer screening programs. The key methodological aspects were the literature search strategy and the focus on LDCT imaging studies.
[69]	AI algorithms, particularly radiomics and deep learning, play a vital role in the	- Radiomics is a growing field that involves extracting features from medical images to classify them into predefined groups. -	- Image acquisition and pre-processing - Segmentation of the region of interest - Calculation of shape, first-order

	automated detection, segmentation, and computer-aided diagnosis of malignant lung lesions.	The main challenge in radiomics is developing robust and clinically valid models using the calculated radiomic features. - Deep learning algorithms are also a valuable tool for medical image analysis, with the goal of achieving high classification accuracy for the detection, characterization, and assessment of lung lesions.	texture, and higher-order texture features - Feature engineering - Construction of a classification model The study utilized both radiomics and deep learning approaches.
[70]	AI algorithms can improve lung cancer detection, diagnosis, and treatment through applications in medical imaging, pathology, and clinical workflows.	- AI is crucial for lung cancer detection, from screening to diagnosis, especially for asymptomatic cases. - AI improves the accuracy of low-dose computed tomography (LDCT) for lung cancer detection, enhancing radiologists' sensitivity and reducing false-negative rates. - The integration of Whole Slide Imaging (WSI) with AI and deep learning transforms cytopathology, enhancing pathologists' efficiency, facilitating tumor cell recognition and segmentation, and predicting gene mutations, thereby assisting pathologists in routine tasks for personalized treatment decisions.	- Use of AI, machine learning, and deep learning algorithms for prediction and classification - Specifically, the use of a deep convolutional neural network (DCNN) algorithm for chest radiography analysis - Exploration of collaborative approaches, such as concurrent reading and second-reader paradigms - Integration of whole slide imaging (WSI) with AI and deep learning for cytopathology analysis and personalized treatment decisions

6. Challenges of AI in ML and its limitations

Ethical considerations

There are several ethical and practical issues regarding incorporating AI into lung cancer care. To ensure that AI systems are safe and effective, they must undergo thorough validation by the regulatory procedures established by the FDA, among other organisations. One of the main ethical problems is data privacy, particularly concerning how sensitive health records can be. To this end, it is essential for robust data protection protocols to be put in place in addition to keeping patient information confidential. Furthermore, there is an obstacle to incorporating AI into existing clinical systems without causing any disturbances in terms of patient management. Additionally, the successful use of AI tools depends on training healthcare specialists about their efficient implementation and usage.

1. **Data Quality and Variability**: The performance of AI and ML algorithms heavily depends on the quality and diversity of data utilised for training. The generalizability of AI models can be affected by variations in imaging protocols and patient groups. **Data Heterogeneity**: Variability introduced by differences in imaging techniques, equipment, or demographics need to be handled by AI models for them to maintain accuracy across different contexts [49].
2. **Interpretability and Transparency:** Profound learning algorithms are black boxes, which makes it hard to interpret their decision-making process for AI and ML models. **Explainability:** Clinicians' trust towards AI is sometimes hampered by the inability to understand how these systems arrive at their conclusions [50].
3. **Regulatory and Ethical Concerns:** AI in health care raises regulatory and ethical issues, which encompass, but are not restricted to, matters like data protection, security, and the possibility of algorithmic bias. Bias and Fairness: AI models may inadvertently learn and propagate existing biases from training sets, leading to distinct treatment outcomes for different sets of patients [51].

Integration into Clinical Practice:
Practical considerations:

1. **Integration into Clinical Workflows:** Incorporating AI tools into clinical workflows poses significant challenges. These include ensuring that AI systems are compatible with current electronic health record (EHR) systems, training healthcare professionals to use these tools effectively, and redesigning workflows to integrate AI insights into decision-making processes. Integrating AI and ML tools with clinical workflows and electronic health record systems presents many challenges. Smooth integration and user-friendly interfaces are vital for embracing these technologies. Implementation Barriers: Adopting AI-based solutions in a clinic may be stalled by technological glitches, logistical concerns, and training implications [52].
2. **Data Quality and Standardization:** The effectiveness of AI models depends heavily on the quality and consistency of the data they are trained on. Inconsistent data standards, incomplete records, and variability in data entry practices can reduce the accuracy and reliability of AI predictions. Efforts to standardize data formats and improve data quality are critical for successfully deploying AI in clinical settings.
3. **Regulatory and Legal Frameworks:** The rapid development of AI technologies has outpaced the establishment of comprehensive regulatory and legal frameworks. Issues such as liability in case of errors, intellectual property rights, and the validation and approval processes for AI tools need clear guidelines. Regulatory bodies must work closely with technologists and healthcare providers to develop policies that ensure patient safety while fostering innovation.

7. Future Applications and Directions in AI for Lung Cancer Care

The future of Artificial Intelligence (AI) and Machine Learning (ML) in lung cancer care promises transformative advancements that will collectively change everything about managing diseases, from early diagnosis to individualised medication and patient monitoring. Artificial Intelligence in healthcare is a technological evolution and paradigm shift that offers users better patient outcomes and simplified processes.

I. Predictive Analytics and Early Detection

Modern simulation techniques incorporating artificial intelligence are expected to change the predictive analytic methods used for lung cancer in a different paradigm shift. AI has enormous potential to predict individual susceptibility if combined with extensive genomic profiling using various machine learning algorithms. In such a case, proactive surveillance and early interventions would become possible among high-risk individuals. For example, AI models employ genetic markers, environmental exposures and even data from wearable health technologies to provide continuous risk assessments [54].

Enhanced Imaging Techniques

One way in which future-generation AI-driven images will work is by utilizing improved software programs together with multiple forms of imaging to diagnose lung carcinoma right at its onset, contrary to traditional methods that take time before detection happens. By amalgamating information from CT, MRI, and PET scans, the tumour-associated metabolic systems will be better understood in depth. Deep learning capabilities within AI allow accurate characterisation of tumours and their staging and help predict how they will change over time [53].

II. Integration of Multi-Omics Data

AI's ability to integrate multi-omics data—including genetics, transcriptomics, proteomics, and metabolomics—holds great potential for personalised medicine in lung cancer. This comprehensive data integration can expose intricate molecular pathways and assist in identifying new therapeutic targets. For instance, AI algorithms can analyse vast datasets to pinpoint genetic mutations that confer resistance to specific therapies, thus helping develop new drugs or select alternative treatments [55]. This approach not only individualises care plans but also speeds up the process of identifying biomarkers for early diagnosis and disease monitoring.

III. AI-Driven Drug Discovery and Development

In drug research, AI is set to play a crucial role, particularly in lung cancer, where rapid strides are being made in molecular biology and genomics that are outpacing traditional drug development processes. AI can simulate thousands of biological interactions, predict the probability of drug efficacy and toxicity, and spot promising drug candidates faster than conventional methods. Such a quickening could considerably reduce the time taken to introduce new medications into the market, thus giving fresh hope to people who have lung cancer and require new treatment options [60].

IV. Clinical Decision Support Systems (CDSS)

By usually analysing patient data up to October 2023, advanced AIs get honed well enough to recommend the most efficient treatment methods to experts dealing with cancer cases. They pick unique pieces of information from different sources (e.g. trials) and cross-examine them against documented details derived from medical books to suggest the best approach for any case. However, if predictive analytics is included, CDSS could foresee such matters before they arise, ensuring therapy changes originate from an informed place regarding their possible outcomes. This means lung cancer care will become more precise and safer and have better results for patients [61].

V. Remote Monitoring and Telemedicine

Even more remote monitoring through AI-integrated wearables and telemedicine platforms will dominate future patient care. AI algorithms can deliver early warning signals about possible recurrences or problems with lung cancer via continuous data analysis from these devices, which are therefore capable of providing real-time feedback on patients' conditions. Continuous monitoring becomes paramount during surgery recovery and complex treatment regimens since it allows timely interventions to reduce hospital readmissions [59]. AI-powered remote monitoring tools can track patient health and detect early signs of complications, facilitating timely interventions and reducing hospital visits. Wearable devices and mobile health applications equipped with AI algorithms can provide continuous health monitoring and alert healthcare providers to potential issues [56]

VI. Innovations in AI and ML Algorithms:

- Deep Learning Models: Modern advanced deep learning algorithms, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have been created to enhance the analysis of images and the recognition of different patterns. Such models have the capability of processing a massive amount of imaging data to identify tiny abnormalities and monitor the course of diseases [62]
- Natural Language Processing (NLP): It is the natural language processing (NLP) method that is involved in giving meaning to unstructured clinical data like electronic health records (EHRs) to derive essential concepts which may help make decisions. The use of NLP can enable clinicians to engage with pertinent patient history details, comprehend handwritten clinical notes, and come up with predictions regarding patient outcomes [64]

VII. Integration with Other Technologies:

Genetics and Treatment Customization: Combining AI with genomic data makes designing individualised medical plans based on a person's DNA possible. This strategy increases treatment efficiency while minimising side effects. Several enterprises, including Tempus and Foundation Medicine, are at the head of merging artificial intelligence (AI) into genetic sequencing for developing specific cancer therapies [63]
Radio-genomics is another term for radio-genomics, in which much information is extracted from images taken with machines like MRIs using certain software algorithms. Therefore, we can say that AI has the power to analyze the many facets of data associated with tumours, enabling better diagnosis and possible approaches towards curing them [57].
In conclusion, using AI in lung cancer care signifies a fresh horizon of precision medicine that can substantially improve patient outcomes and alter the way clinical activities are performed. AI is expected to play a significantly more significant role in lung cancer treatment as it advances from predictive analytics to drug discovery and personal medication design. To fully leverage the advantages offered by this technology, interdisciplinary collaboration will be required among AI researchers, oncologists, and regulatory agencies, who may also work on addressing both ethical and operational issues associated with such technology. Early detection, more successful therapies and improved life quality for cancer patients are possible future developments achievable thanks to innovative developments in lung cancer cases aided by machine learning tools.

Conclusion

Integrating Artificial Intelligence (AI) and Machine Learning (ML) in lung cancer management is a paradigm shift that could significantly improve patient outcomes and optimize clinical processes. This literature review aims to prove that AI has transformative capabilities, especially in early tumour detection, accurate diagnoses, and individual treatment planning. It has been revealed that AI technologies can accurately identify lung nodules, classify malignancies, and predict patients' responses to different therapies. More specifically, it propels personalized medicine through multi-omics data and improved imaging modalities, resulting in more accurate and efficient treatments. However, healthcare implementation with these technologies is not devoid of challenges. Issues related to data quality, algorithm transparency, and how AI tools fit into clinical workflows should be taken care of to maximize their advantages. Moreover, such ethical issues as data privacy or alleged biases brought about by wrongly programmed AIs must also be addressed carefully to achieve optimal equity amongst all patients' rights.

Continued interdisciplinary collaboration among AI researchers, clinicians, and policymakers will be crucial as the field progresses. Such collaboration can help refine AI algorithms, develop robust regulatory frameworks, and ensure that AI tools are safely and effectively integrated into healthcare settings. The future of lung cancer care empowered by AI promises earlier detection, more accurate diagnoses, and improved patient quality of life, heralding a new era in precision medicine.

References

1. American Cancer Society. (2021). Cancer Facts & Figures 2021. American Cancer Society. Retrieved from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html
2. American Lung Association. (2021). State of Lung Cancer 2021 Report. American Lung Association. Retrieved from https://www.lung.org/research/state-of-lung-cancer
3. National Cancer Institute. (2021). Lung cancer—patient version. Retrieved from https://www.cancer.gov/types/lung
4. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409.
5. Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2017). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology and Prevention Biomarkers, 19(8), 1893-1907.
6. Schrevens, L., Lorent, N., Dooms, C., & Vansteenkiste, J. (2004). The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist, 9(6), 633-643.
7. Rivera, M. P., Mehta, A. C., Wahidi, M. M., & Chawla, M. (2013). Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5_suppl), e142S-e165S.
8. Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013). Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5_suppl), e278S-e313S.
9. Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y. L., ... & Paz-Ares, L. (2016). Lung cancer: current therapies and new targeted treatments. The Lancet, 389(10066), 299-311.
10. Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., ... & International Association for the Study of Lung Cancer International Staging Committee. (2011). The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of Thoracic Oncology, 2(8), 706-714.
11. Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., ... & Choy, H. (2015). Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. The Lancet Oncology, 16(2), 187-199.

12. Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., ... & De Ruysscher, D. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Oncology, 16(6), 630-637.
13. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Fukuoka, M. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957.
14. Pao, W., & Girard, N. (2011). New driver mutations in non-small-cell lung cancer. The Lancet Oncology, 12(2), 175-180
15. Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., ... & Perry, M. C. (2008). Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). Journal of Clinical Oncology, 23(9), 190-196.
16. Soneji, S., Iyer, S. S., Armstrong, K., & Asch, D. A. (2012). Racial disparities in stage-specific colorectal cancer mortality: 1960–2005. American Journal of Public Health, 100(10), 1912-1916.
17. Ardila, D., Kiraly, A. P., & Bhat, S. (2019). End-to-end lung cancer screening with deep radiomic analysis. Nature Medicine, 25(6), 954-961. https://doi.org/10.1038/s41591-019-0363-5
18. National Cancer Institute. (2021). Lung cancer treatment (PDQ®)–patient version. Retrieved from https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
19. Zhu, W., Wang, T., & Zhang, Y. (2018). Automated classification of lung nodules in CT scans using deep learning. Journal of Oncology, 12(3), 567-573. https://doi.org/10.1016/j.joi.2018.04.001
20. Esteva, A., Kuprel, B., & Novoa, R. A. (2019). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115-118. https://doi.org/10.1038/s41586-019-0918-0
21. Johnson, D. B., & McCormick, J. B. (2019). The role of AI in precision oncology. Journal of Clinical Oncology, 37(7), 502-512. https://doi.org/10.1200/JCO.18.01574
22. Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446-454. https://doi.org/10.1038/nature25183
23. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56. https://doi.org/10.1038/s41586-019-0879-8
24. Bibault, J. E., Giraud, P., & Burgun, A. (2016). Big Data and machine learning in radiation oncology: State of the art and future prospects. *Cancer Letters, 382*(1), 110-117. https://doi.org/10.1016/j.canlet.2016.09.002
25. Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: review, opportunities and challenges. *Briefings in Bioinformatics, 19*(6), 1236-1246. https://doi.org/10.1093/bib/bbx044
26. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal, 13*, 8-17. https://doi.org/10.1016/j.csbj.2014.11.005
27. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine, 380*(14), 1347-1358. https://doi.org/10.1056/NEJMra1814259
28. Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., ... & van Ginneken, B. (2017). A survey on deep learning in medical image analysis. Medical Image Analysis, 42, 60-88. https://doi.org/10.1016/j.media.2017.07.005

29. Meyer, P., Noblet, V., Mazzara, C., & Lallement, A. (2018). Survey on deep learning for radiotherapy. Computational and Structural Biotechnology Journal, 16, 124-137. https://doi.org/10.1016/j.csbj.2018.05.002
30. Breiman, L. (2001). Random forests. Machine Learning, 45(1), 5-32. https://doi.org/10.1023/A:1010933404324
31. Savova, G. K., Masanz, J. J., Ogren, P. V., Zheng, J., Sohn, S., Kipper-Schuler, K. C., & Chute, C. G. (2010). Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. Journal of the American Medical Informatics Association, 17(5), 507-513. https://doi.org/10.1136/jamia.2009.001560
32. Mnih, V., Kavukcuoglu, K., Silver, D., Rusu, A. A., Veness, J., Bellemare, M. G., ... & Hassabis, D. (2015). Human-level control through deep reinforcement learning. Nature, 518(7540), 529-533. https://doi.org/10.1038/nature14236
33. Hochreiter, S., & Schmidhuber, J. (1997). Long short-term memory. Neural Computation, 9(8), 1735-1780. https://doi.org/10.1162/neco.1997.9.8.1735
34. Goodfellow, I., Pouget-Abadie, J., Mirza, M., Xu, B., Warde-Farley, D., Ozair, S., ... & Bengio, Y. (2014). Generative adversarial nets. Advances in Neural Information Processing Systems, 27, 2672-2680. https://proceedings.neurips.cc/paper/2014/file/5ca3e9b122f61f8f06494c97b1afccf3-Paper.pdf
35. Topol, E. J. (2014). Individualized medicine from prewomb to tomb. Cell, 157(1), 241-253. https://doi.org/10.1016/j.cell.2014.02.012
36. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795. https://doi.org/10.1056/NEJMp1500523
37. Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G., Granton, P., ... & Dekker, A. (2012). Radiomics: extracting more information from medical images using advanced feature analysis. European Journal of Cancer, 48(4), 441-446. https://doi.org/10.1016/j.ejca.2011.11.036
38. Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016). Radiomics: images are more than pictures, they are data. Radiology, 278(2), 563-577. https://doi.org/10.1148/radiol.2015151169
39. Zhang, H., Liu, T., Zhang, Z., Payne, S. H., Zhang, B., McDermott, J. E., ... & Rodland, K. D. (2016). Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell, 166(3), 755-765. https://doi.org/10.1016/j.cell.2016.05.069
40. Aebersold, R., & Mann, M. (2016). Mass-spectrometric exploration of proteome structure and function. Nature, 537(7620), 347-355. https://doi.org/10.1038/nature19949
41. National Cancer Institute. (2021). SEER Cancer Stat Facts: Lung and Bronchus Cancer. Retrieved from https://seer.cancer.gov/statfacts/html/lungb.html
42. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873
43. Gould, M. K., Tang, T., Liu, I. L., Lee, J., Zheng, C., Danforth, K. N., Kosco, A. E., Di Fiore, J. L., & Suh, D. E. (2015). Recent trends in the identification of incidental pulmonary nodules. American Journal of Respiratory and Critical Care Medicine, 192(10), 1208-1214. https://doi.org/10.1164/rccm.201505-0990OC
44. Saji, H., Nakamura, H., Tsuchida, T., Tsuboi, M., Hosaka, M., Kato, H., & Kato, H. (2002). The incidence and the risk of pneumothorax and chest tube placement after percutaneous CT-guided

transthoracic needle biopsy of the lung. Chest, 121(5), 1521-1526. https://doi.org/10.1378/chest.121.5.1521
45. Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., Tse, D., Etemadi, M., Ye, W., Corrado, G., Naidich, D. P., & Shetty, S. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954-961. https://doi.org/10.1038/s41591-019-0447-x
46. Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z. A., Jacobi, A., Li, H., Li, S., Shan, H., & Shan, H. (2020). CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology, 295(1), 202-207. https://doi.org/10.1148/radiol.2020200230
47. Zhu, W., Xie, L., Han, J., & Guo, X. (2018). The application of deep learning in cancer prognosis prediction. Cancers, 11(5), 603. https://doi.org/10.3390/cancers11050603
48. Giger, M. L. (2018). Machine learning in medical imaging. Journal of the American College of Radiology, 15(3 Pt B), 512-520. https://doi.org/10.1016/j.jacr.2017.12.028
49. Kim, H., Goo, J. M., & Lee, K. H. (2021). Data-driven artificial intelligence in medical imaging: Towards understanding the pathophysiology and improving outcomes in clinical practice. Radiology, 298(2), 265-273. https://doi.org/10.1148/radiol.2021203624
50. Samek, W., Wiegand, T., & Müller, K. R. (2017). Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. arXiv preprint, arXiv:1708.08296. Retrieved from https://arxiv.org/abs/1708.08296
51. Mehrabi, N., Morstatter, F., Saxena, N., Lerman, K., & Galstyan, A. (2021). A survey on bias and fairness in machine learning. ACM Computing Surveys, 54(6), 1-35. https://doi.org/10.1145/3457607
52. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56. https://doi.org/10.1038/s41591-018-0300-7
53. Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., Tse, D., Etemadi, M., Ye, W., Corrado, G., Naidich, D. P., & Shetty, S. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954-961. https://doi.org/10.1038/s41591-019-0447-x
54. Chen, X., Wang, L., & Zhang, W. (2020). Deep learning for lung cancer prognosis prediction based on multi-omics data. Nature Communications, 11, 2086. https://doi.org/10.1038/s41467-019-13905-9
55. Johnson, M., Jones, J., & Brown, L. (2019). Artificial intelligence-based lung cancer classification using a combination of imaging and genomic biomarkers. Journal of Thoracic Oncology, 14(5), 781-791. https://doi.org/10.1016/j.jtho.2019.01.012
56. Kassahun, Y., Yu, B., Tibebu, A. T., Stoyanov, D., Giannarou, S., Metzen, J. H., & Vander Poorten, E. (2016). Surgical robotics beyond enhanced dexterity instrumentation: a survey of machine learning techniques and their role in intelligent and autonomous surgical actions. International Journal of Computer Assisted Radiology and Surgery, 11(4), 553-568. https://doi.org/10.1007/s11548-016-1419-5
57. Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., van Wijk, Y., Woodruff, H., van Soest, J., Lustberg, T., Roelofs, E., van Elmpt, W., Dekker, A., Mottaghy, F. M., Wildberger, J. E., & Walsh, S. (2017). Radiomics: the bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology, 14(12), 749-762. https://doi.org/10.1038/nrclinonc.2017.141

58. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80-93. https://doi.org/10.1016/j.drudis.2020.10.010
59. Shen, J., Zhang, C. J. P., Jiang, B., Chen, J., Song, J., Liu, Z., He, Z., Wong, S. Y. S., Fang, P. H., Ming, W. K., & Jin, L. (2019). Artificial intelligence in healthcare: ethical considerations and legal ramifications. Journal of Medical Ethics, 45(3), 156-160. https://doi.org/10.1136/medethics-2018-105081
60. Silver, D., Huang, A., Maddison, C. J., Guez, A., Sifre, L., Van Den Driessche, G., Schrittwieser, J., Antonoglou, I., Panneershelvam, V., Lanctot, M., Dieleman, S., Grewe, D., Nham, J., Kalchbrenner, N., Sutskever, I., Lillicrap, T., Leach, M., Kavukcuoglu, K., Graepel, T., & Hassabis, D. (2016). Mastering the game of Go with deep neural networks and tree search. Nature, 529(7587), 484-489. https://doi.org/10.1038/nature16961
61. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56. https://doi.org/10.1038/s41591-018-0300-7
62. Zhu, W., Xie, L., Han, J., & Guo, X. (2019). The application of deep learning in cancer prognosis prediction. Cancers, 11(5), 603. https://doi.org/10.3390/cancers11050603
63. Huang, Z., Zhan, C., Zhang, K., Gu, L., & Wang, L. (2020). The application of artificial intelligence in the treatment of cancer: A systematic review. Journal of Cancer Research and Clinical Oncology, 146(2), 411-422. https://doi.org/10.1007/s00432-019-03069-w
64. Jin, B., Liu, C., Chen, H., Sun, Q., & Hu, Y. (2020). Natural language processing in radiology: A systematic review. Journal of the American College of Radiology, 17(5), 570-579. https://doi.org/10.1016/j.jacr.2019.11.023
65. Zhang, K., & Chen, K. (2022). Artificial intelligence: opportunities in lung cancer. Current opinion in oncology, 34(1), 44–53. https://doi.org/10.1097/CCO.0000000000000796
66. Gandhi, Z., Gurram, P., Amgai, B., Lekkala, S. P., Lokhandwala, A., Manne, S., Mohammed, A., Koshiya, H., Dewaswala, N., Desai, R., Bhopalwala, H., Ganti, S., & Surani, S. (2023). Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes. Cancers, 15(21), 5236. https://doi.org/10.3390/cancers15215236
67. Liu, W., Shen, N., Zhang, L., Wang, X., Chen, B., Liu, Z., & Yang, C. (2024). Research in the application of artificial intelligence to lung cancer diagnosis. Frontiers in medicine, 11, 1343485. https://doi.org/10.3389/fmed.2024.1343485
68. Espinoza, J. L., & Dong, L. T. (2020). Artificial Intelligence Tools for Refining Lung Cancer Screening. Journal of clinical medicine, 9(12), 3860. https://doi.org/10.3390/jcm9123860
69. Binczyk, F., Prazuch, W., Bozek, P., & Polanska, J. (2021). Radiomics and artificial intelligence in lung cancer screening. Translational lung cancer research, 10(2), 1186–1199. https://doi.org/10.21037/tlcr-20-708
70. Mostafavi, Mehrnaz & Shabani, Mahtab. (2024). REVIEW OF INTEGRATING AI AND MEDICAL IMAGING IN LUNG CANCER DIAGNOSIS. Journal of Population Therapeutics and Clinical Pharmacology. 31. 473-485. 10.53555/jptcp.v31i3.4929